Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coherus BioSciences Inc.

www.coherus.com

Latest From Coherus BioSciences Inc.

Keeping Track: Tauvid, Oriahnn, Artesunate Clear US FDA, Along With Trio Of Pediatric Approvals

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Approvals US FDA Performance Tracker

Stada Ranibizumab Deal Doesn’t Change Coherus’ Aspirations

With one foot already in oncology, biosimilars player Coherus is looking to make a splash in ophthalmology with ambitions to launch rivals to Lucentis and Eylea, as well as Avastin, in the US in the coming years. The US-based firm has acknowledged the competition it faces for biosimilars to Lucentis as Bausch Health picked up rights to Stada and Xbrane’s candidate earlier this month.

Biosimilars Strategy

Coherus Eyes Further Biosimilar Candidates But Urges Caution

Coherus BioScienes has an extra $200m or so in the bank thanks to a financing round complete last month. The company has committed to building out its pipeline of biosimilar candidates, while eyeing the opportunity to increase its share in the biosimilar pegfilgrastim market.

Strategy Sales & Earnings

Finance Watch: Biopharma Fundraising Impact Expected, But Not Apparent Yet

While COVID-19 shocked global financial markets and is expected to impact biopharma fundraising, investment in drug developers continues, including through two new venture capital funds totaling nearly $2bn. Also, Coherus issues debt to fund deals and MOMA launches with $86m in VC cash.

Financing Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Dermatology
  • Gastrointestinal
  • Immune Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Ophthalmic
  • Alias(es)
  • BioGenerics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Coherus BioSciences Inc.
  • Senior Management
  • Dennis Lanfear, Chmn., Pres. & CEO
    Jean-Frederic Viret, PhD, CFO
    Vladimir Vexler, PhD, CSO
    Barbara K Finck, MD, Acting CMO
    Vince Anicetti, COO
    Erik Wiberg, EVP, Corp. Dev.
  • Contact Info
  • Coherus BioSciences Inc.
    Phone: (800) 794-5434
    333 Twin Dolphin Dr., Ste. 600
    Redwood City, CA 94065
    USA
UsernamePublicRestriction

Register